Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Southern Asia has been steadily growing in recent years.
Customer preferences: Patients in Southern Asia who require immunosuppressants often suffer from autoimmune diseases, such as lupus or rheumatoid arthritis, or have undergone organ transplants. As a result, they require medication that can effectively suppress their immune system to prevent their body from attacking itself or rejecting the new organ.
Trends in the market: India and Pakistan are the largest markets for immunosuppressants in Southern Asia, with a growing demand for these drugs due to an increase in organ transplants. The use of generic drugs is also becoming more prevalent in the region due to their affordability. However, there is still a preference for branded drugs, especially among higher-income patients.
Local special circumstances: In Pakistan, the government provides immunosuppressants free of cost to patients who have undergone organ transplants. This has led to an increase in demand for these drugs, as patients who would not have been able to afford them otherwise are now able to access them.
Underlying macroeconomic factors: The healthcare sector in Southern Asia is growing, with an increase in government spending on healthcare infrastructure and services. This has led to an increase in demand for immunosuppressants, as more patients are able to access healthcare services and receive the necessary treatment. Additionally, the rise of medical tourism in the region has also contributed to the growth of the immunosuppressants market, as more patients from other countries come to Southern Asia for organ transplants. In conclusion, the immunosuppressants market in Southern Asia is growing due to an increase in demand for these drugs, driven by an increase in organ transplants and a growing healthcare sector. The use of generic drugs and government initiatives to provide free medication to patients have also contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
